Short Interest in OKYO Pharma Limited (NASDAQ:OKYO) Drops By 17.8%

OKYO Pharma Limited (NASDAQ:OKYO) was the recipient of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 179,200 shares, a drop of 17.8% from the March 15th total of 217,900 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily volume of 183,900 shares, the short-interest ratio is presently 1.0 days.

OKYO Pharma Stock Up 2.1 %

OKYO traded up $0.02 during trading on Tuesday, reaching $1.19. 3,017 shares of the stock were exchanged, compared to its average volume of 114,979. The business’s 50 day moving average price is $1.23 and its two-hundred day moving average price is $1.13. OKYO Pharma has a 1 year low of $0.81 and a 1 year high of $1.74.

Institutional Investors Weigh In On OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. FNY Investment Advisers LLC acquired a new position in shares of OKYO Pharma Limited (NASDAQ:OKYO) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 20,000 shares of the company’s stock, valued at approximately $25,000. FNY Investment Advisers LLC owned about 0.06% of OKYO Pharma as of its most recent SEC filing. 2.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a research note on Tuesday, February 18th.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.